Related Experiment Videos
Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience.
1Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. k-mcvary@northwestern.edu
The Journal of Urology
|January 13, 2006
Summary
Alfuzosin effectively treats lower urinary tract symptoms (LUTS) in benign prostatic hyperplasia (BPH) long-term. This alpha-blocker improves symptoms and quality of life with good tolerability, especially extended-release formulations.
Area of Science:
- Urology
- Pharmacology
Background:
- Benign prostatic hyperplasia (BPH) is a common condition causing lower urinary tract symptoms (LUTS).
- Alpha(1)-adrenergic receptor blockers are a first-line treatment for BPH-related LUTS.
Purpose of the Study:
- To evaluate the long-term efficacy and safety of alfuzosin for treating LUTS in BPH.
- To compare different alfuzosin formulations regarding efficacy and tolerability.
Main Methods:
- A comprehensive literature search of MEDLINE, PubMed, and scientific meeting proceedings from 1974 to 2004.
- Keywords included BPH, alfuzosin, LUTS, alpha-blockers, long-term, and adverse events.
Main Results:
- Alfuzosin, particularly extended-release formulations, significantly improves LUTS in BPH patients.
- Newer alfuzosin formulations show improved selectivity and tolerability with fewer vasodilatory effects compared to older agents.
- Long-term alfuzosin use maintains symptom relief, reduces residual urine, and lowers the risk of urinary retention.
Conclusions:
- Alfuzosin provides sustained relief from BPH symptoms and improves quality of life.
- Most side effects are mild and transient, occurring early in treatment.
- Extended-release alfuzosin offers convenience and better vasodilatory tolerability.